Send to

Choose Destination
Ther Adv Hematol. 2011 Jun;2(3):129-39. doi: 10.1177/2040620711407675.

Symptom Burden and Quality of Life in Patients with Follicular Lymphoma undergoing Maintenance Treatment with Rituximab Compared with Observation.

Author information

ACORN Research, LLC, Memphis, TN, USA.



The impact on health related quality of life (HRQoL) of rituximab maintenance (R-M) versus observation (OBS) after induction for treatment of follicular lymphoma (FL) is unclear.


We reviewed the charts of 137 patients (53% female, 87% White, age 61.0 ± 12.4 years) who received either R-M (n = 53) or OBS (n = 84) after chemotherapy induction for newly diagnosed FL at community oncology practices within the US. Patients (65% with advanced disease; 48% with a high FLIPI score [3-5]) had completed ≥1 Patient Care Monitor HRQoL survey in the period following front-line therapy, and were excluded if they had progressed during front-line therapy.


Linear mixed models showed that postinduction, most symptoms were stable, with patients on R-M reporting HRQoL that was equal to that reported by OBS patients.


Among R-M patients, receipt of rituximab was associated with improved psychological symptoms.


Rituxan; follicular lymphoma; maintenance therapy; rituximab; symptoms

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center